Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy 

Published byIrma Halászné Modified over 5 years ago

Similar presentations

Presentation on theme: "The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy "— Presentation transcript:

1 The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi Soh, MD, PhD, Katsuyuki Hotta, MD, PhD, Kuniaki Katsui, MD, PhD, Hiromasa Yamamoto, MD, PhD, Seiichiro Sugimoto, MD, PhD, Takahiro Oto, MD, PhD, Susumu Kanazawa, MD, PhD, Katsuyuki Kiura, MD, PhD, Shinichiro Miyoshi, MD, PhD  The Annals of Thoracic Surgery  Volume 102, Issue 3, Pages (September 2016) DOI: /j.athoracsur Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

2 Fig 1 Kaplan-Meier curves showing the overall survival (OS) and recurrence-free survival (RFS) rates for the entire population. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

3 Fig 2 Kaplan-Meier curves showing the overall survival (OS) rate for the entire population stratified by (A) clinical and (B) pathological stages. The patients with T0 N1 M0 (n = 4) and T0 N2 M0 (n = 6) were classified as pathologic y-stage (yp-stage) IIA and yp-stage IIIA. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

4 Fig 3 Kaplan-Meier curves showing the overall survival (OS) and recurrence-free survival (RFS) rates for patients with biopsy-proven mediastinal metastasis. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

5 Fig 4 Kaplan-Meier curves showing the (A) overall survival (OS) and (B) recurrence-free survival (RFS) rates for patients in the median sternotomy (MS) and lateral thoracotomy (LT) groups. The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur ) Copyright © 2016 The Society of Thoracic Surgeons Terms and Conditions

Download ppt "The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy "

Similar presentations

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.

Advantage of Induction Chemoradiotherapy for Lung Cancer in Securing Cancer-Free Bronchial Margin  Hiroki Sato, MD, Shinichi Toyooka, MD, PhD, Junichi.
Elizabeth A. David, MD, David T

Elizabeth A. David, MD, David T
Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients  Chi-Fu Jeffrey Yang, MD, Nicholas R. Mayne,
Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,

Treating Constrictive Pericarditis in a Chinese Single-Center Study: A Five-Year Experience  Yiyun Lin, MD, Mi Zhou, MMS, Jian Xiao, MD, Bin Wang, MD,
Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease  Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.
Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer 
Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer  Yoichi.

Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer  Yoichi.
MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl.

MicroRNA Expression Profiling of Esophageal Cancer Before and After Induction Chemoradiotherapy  Michael Augustine Ko, MD, PhD, Guan Zehong, MS, Carl.
Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F
Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,

Missed Intrapulmonary Lymph Node Metastasis and Survival After Resection of Non- Small Cell Lung Cancer  Matthew P. Smeltzer, PhD, Nicholas Faris, MDiv,
Joshua E. Rosen, BASc, Hari B

Joshua E. Rosen, BASc, Hari B
Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E

Zhiqiang Xue, MD, Fengying Wu, MD, Karlyn E
Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B

Elliot Wakeam, MD, MPH, Meredith Giuliani, MBBS, MEd, Natasha B
Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD 
Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,

Clinical Prognosis of Superior Versus Basal Segment Stage I Non-Small Cell Lung Cancer  Yoshinori Handa, MD, Yasuhiro Tsutani, MD, PhD, Norifumi Tsubokawa,
Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy  Colin Schieman, MD, Dennis A. Wigle, MD, PhD,

Salvage Resections for Recurrent or Persistent Cancer of the Proximal Esophagus After Chemoradiotherapy  Colin Schieman, MD, Dennis A. Wigle, MD, PhD,
Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis  Takekazu Iwata, MD, PhD, Shigetoshi Yoshida,

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis  Takekazu Iwata, MD, PhD, Shigetoshi Yoshida,
Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.
Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J
Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection  Bing-sheng Sun, MD, PhD, Yue.

Similar presentations

Ads by Google